The course of COVID-19 in allergic rhinitis patients receiving allergen spesific immunotherapy
Allergy: European Journal of Allergy and Clinical Immunology
; 78(Supplement 111):72, 2023.
Article
in English
| EMBASE | ID: covidwho-2291596
ABSTRACT
Background:
The aims of presenting study were trying to expose the course of SARS-CoV- 2 (severeacute respiratory syndrome-related coronavirus) in patients with allergic rhinitis (AR),to compare the prevalence of SARS-CoV- 2 infection, hospitalization and pneumoniarates in patients with AR receiving allergen immunotherapy (AIT) and patients did notreceiving AIT (non-receivers) and to define possible risk factors for SARS-CoV- 2positivity in patients with AR. Method(s) A total of 419 patients with AR who were being followed- up in a tertiary allergy clinicbetween 1 June 2020 and 31 December 2020, were selected for the study. Onlypatients who were receiving active-continuous treatment for allergic rhinitis during thestudy period, were included in the study. Result(s) Seventy-nine patients (18.9%) became infected with the SARS-CoV- 2 [32 patients(19.6%) in AR patients with AIT and 47 patients (19.0%) in non-receivers] and the rateof pneumonia was 2.4% [12.7% of SARS-CoV- 2 (+) patients]. There was no significantdifference was determined between the AR patients with AIT and the non-receivers inregard of the rate of SARS-CoV- 2 infection, pneumonia and hospitalization (p 0.864, p 0.081, p 0.113). There was a significant difference between the groups in terms ofgender, duration of disease, sensitivity to allergens (atopy) and serum IgE levels (p0.009, p 0.001, p 0.001 and p 0.001). The accompanying comorbidities, eosinophilcount, AIT and duration of AIT were not found to be associated with an increased riskSARS-CoV- 2 PCR positivity. However, female gender was shown to be associatedwith an decreased risk for SARS-CoV- 2 PCR positivity (OR, 0.571;95% confidenceinterval, 0.330-0.987;p 0.045) Conclusion(s) The course of SARS-CoV- 2 is similar in patients with AR who underwent AIT andpatients with AR who did not undergo AIT, and AIT does not seem to increase the riskfor SARS-CoV- 2 infection.
adult; allergic rhinitis; allergy; comorbidity; conference abstract; controlled study; coronavirus disease 2019; desensitization; female; gender; gene expression; hospitalization; human; human tissue; immunoglobulin blood level; immunotherapy; major clinical study; male; nonhuman; pneumonia; prevalence; respiratory tract disease; risk factor; Severe acute respiratory syndrome coronavirus 2; allergen; endogenous compound; immunoglobulin E
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Type of study:
Prognostic study
Language:
English
Journal:
Allergy: European Journal of Allergy and Clinical Immunology
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS